Featured Research

from universities, journals, and other organizations

Cancer-causing virus exploits key cell-survival proteins

Date:
February 23, 2011
Source:
Ohio State University Medical Center
Summary:
The human T-lymphotropic virus type 1, a cancer-causing retrovirus, exploits key proteins in host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study. The virus, which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that targets two important cell proteins, one involved in DNA damage repair, the other involved in the destruction of proteins within the cell.

A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) and Ohio State's College of Veterinary Medicine.

The human T-lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that is essential for the retrovirus to establish an infection. This study found that this viral protein targets two important cell proteins: ATM, a key player in a cell's response to DNA damage, and REG-gamma, which marks proteins within the cell for destruction.

"Our findings suggest that the p30 viral protein prolongs the survival of host cells through this interaction with ATM and REG-gamma, and the longer a virus-infected cell survives, the better chance the virus has to spread, " says principal investigator Michael Lairmore, DVM, PhD, professor of veterinary biosciences and associate director for shared resources at the OSUCCC -- James.

The findings were published recently in the Journal of Biological Chemistry.

An estimated 20 million people worldwide are infected by HTLV-1, and about five percent of them will develop adult T-cell leukemia or lymphoma, or one of a variety of inflammatory disorders.

Lairmore and his colleagues used cell lines and a variety of biochemical assays to identify cellular binding partners of p30.

They discovered the following:

  • p30 specifically binds to cellular ATM (ataxia-telangiectasia mutated), a key regulator of DNA damage responses and cell cycle control, and to REG-gamma, a nuclear proteasome activator.
  • Under stressful conditions, p30 levels are associated with lower ATM levels and increased cell survival.
  • The expression of p30 changes in concert with expression of REG-gamma, suggesting that overexpression of REG-gamma enhances levels of p30.
  • p30 forms a complex with ATM and REG-gamma.

Funding from the National Cancer Institute supported this research.

Other Ohio State researchers involved in this study were Rajaneesh Anupam, Antara Datta, Matthew Kesic, Kari Green-Church, Nikolozi Shkriabai and Mamuka Kvaratskhelia.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Anupam R, Datta A, Kesic M, Green-Church K, Shkriabai N, Kvaratskhelia M, Lairmore MD. Human T-lymphotropic virus type 1 p30 interacts with REG{gamma} and modulates ataxia telangiectasia mutated to promote cell survival. J Biol Chem, 2011 Jan 7 [link]

Cite This Page:

Ohio State University Medical Center. "Cancer-causing virus exploits key cell-survival proteins." ScienceDaily. ScienceDaily, 23 February 2011. <www.sciencedaily.com/releases/2011/02/110222122101.htm>.
Ohio State University Medical Center. (2011, February 23). Cancer-causing virus exploits key cell-survival proteins. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2011/02/110222122101.htm
Ohio State University Medical Center. "Cancer-causing virus exploits key cell-survival proteins." ScienceDaily. www.sciencedaily.com/releases/2011/02/110222122101.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins